Anshi Biological has received inquiries for its IPO on the Science and Technology Innovation Board.

On October 19th, Beijing Anchoring Biotechnology Co., Ltd. (referred to as Anchoring Biotechnology) applied for a change in the review status of the Shanghai Stock Exchange Science and Technology Innovation Board listing to "inquiry received". Huatai United Securities is the sponsor institution, and the company plans to raise 2.45 billion yuan. The prospectus shows that Anchoring Biotechnology is an innovative biopharmaceutical company entering the commercialization stage, focusing on disease areas such as tumors where there are significant unmet clinical needs. The company is dedicated to providing high-quality innovative anti-tumor drugs through efficient independent research and development to improve the quality of life for patients. Focusing on important tumor-driving genetic pathways such as MET, EGFR, ROS1, NTRK, HER2, and RAS, the company has established a multi-layered innovative drug pipeline with industry competitiveness and commercial potential. As of the signing date of this prospectus, one product from the company's innovative drug pipeline has received market approval in China, one product is in the process of new drug market approval, and two products are in clinical research stage. The company is conducting multiple clinical trials globally, including four Phase III clinical trials. Van Bi Rui (Beritinib) and And Aitinib are the company's main products, showing superior treatment efficacy and safety advantages over existing therapies in clinical trials and preclinical studies, with outstanding potential to fill treatment gaps or iterate existing treatment regimens. The company has also independently developed multiple innovative drug molecules with important clinical value and leading progress in the same field, advancing them to clinical research or clinical application stage. These include: a new generation MET-TKI (ANS01) targeting the treatment gap after MET-TKI resistance, a innovative ROS1/NTRK-TKI (ANS03) expected to overcome common drug resistance mutations and complex mutations, a new generation EGFR-TKI (ANS02) targeting primary and secondary drug resistance mutations in multiple EGFR, and a new generation highly potent, broad-spectrum, low-toxicity, highly selective HER2-TKI (ANS05) aimed at overcoming HER2 abnormalities. Financially, Anchoring Biotechnology achieved net profits of approximately -164 million yuan, -283 million yuan, -479 million yuan, and -91.65 million yuan in the fiscal years of 2022, 2023, 2024, and January to March 2025, respectively.